The American Society for the Study of Hepatology (AASLD) recently released the "2023 Practice Guidelines for the Treatment of Hepatocellular Carcinoma (HCC)". The "6-12 Model" study by Professor Han Guohong from the Digestive Disease Hospital of Xi'an International Medical Center Hospital was cited to develop local treatment guidelines for liver cancer. The results were published in the Journal of Hepatology in 2019, making it the first international model study on the prognosis of TACE standard populations.

The American Society for the Study of Hepatology (AASLD) is one of the most authoritative non-profit academic organizations in the international field of liver disease. Along with the Asia Pacific Society of Hepatology (APASL) and the European Society of Hepatology (EASL), AASLD is one of the top three global liver disease academic organizations. The clinical practice guidelines released annually provide important guidance and reference opinions for the clinical diagnosis and treatment decisions of liver disease physicians worldwide.

TACE is one of the important means of interventional therapy for liver cancer, and its combination of targeted and immunotherapy has a definite therapeutic effect. In the history of over 40 years of clinical application, the "6-12 model" first proposed efficacy prediction for the TACE standard population. It divides patients into three subtypes: low load, medium load, and high load based on the sum of the maximum tumor diameter and the number of tumors, helping clinicians more accurately screen patients suitable for TACE treatment.

The advantage of this model is that the modeling research population is the ideal TACE population recommended by the guidelines, which can achieve individual prognosis prediction of liver cancer efficacy, and its predictive ability is superior to other previous prediction models. Its advantages have been verified by experts from multiple countries such as Germany, France, Thailand, and South Korea, and have been applied in many ongoing liver cancer related experiments.

Expert Introduction

Professor Han Guohong has been engaged in the clinical, teaching, and scientific research of interventional therapy for digestive system diseases for over 30 years, making groundbreaking and sustained contributions to the development of liver cancer intervention. He rooted himself in the frontline of clinical practice and completed tens of thousands of liver cancer intervention surgeries. Created the "6-12" scoring model for the first time; Established the real world TACE specific personalized prediction and risk stratification model with the largest international sample size; Taking the lead in conducting clinical research on intervention combined with targeted and combined immunotherapy for liver cancer, and participating in more than 20 liver cancer related clinical trials both domestically and internationally; Completed more than 10 national science and technology awards, including key international cooperation projects. He has won the Innovation Team Award of the National Science and Technology Progress Award and the First Prize of the Military Science and Technology Progress Award, and has published 155 SCI papers in international authoritative journals such as Nature and Lancet, with a maximum impact factor of 73 points. The relevant results have been included in 9 international guidelines, including the American Society of Hepatology and the European Society of Hepatology.